Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:lanreotide
|
| gptkbp:administeredBy |
injection
|
| gptkbp:ATCCode |
H01CB03
|
| gptkbp:brand |
gptkb:lanreotide
|
| gptkbp:form |
Somatuline Autogel
Somatuline Depot |
| gptkbp:hasApprovalBy |
gptkb:FDA
gptkb:EMA |
| https://www.w3.org/2000/01/rdf-schema#label |
Somatuline
|
| gptkbp:isAdministeredEvery |
4 weeks
|
| gptkbp:isApprovedDrug |
true
|
| gptkbp:isSomatostatinAnalog |
true
|
| gptkbp:manufacturer |
gptkb:Ipsen
|
| gptkbp:sideEffect |
nausea
diarrhea abdominal pain injection site reaction gallstones |
| gptkbp:usedFor |
gptkb:carcinoid_syndrome
acromegaly neuroendocrine tumors gastroenteropancreatic neuroendocrine tumors |
| gptkbp:wasFirstApprovedIn |
2007 (US)
|
| gptkbp:bfsParent |
gptkb:Ipsen
|
| gptkbp:bfsLayer |
7
|